Theravance Biopharma Outlines Growth Strategy at Investment Conference

Theravance Biopharma ( (TBPH) ) has issued an announcement.

Theravance Biopharma, Inc. is set to engage in a Fireside Chat at the H.C. Wainwright Global Investment Conference, with management conducting one-on-one meetings. The company is leveraging its portfolio, including the first-in-class nebulized LAMA YUPELRI for COPD, potential nOH therapy Ampreloxetine, and the triple therapy TRELEGY, to drive growth and revenue. With multiple value-generating milestones on the horizon, including significant TRELEGY sales milestones and royalty payments, Theravance is strategically positioned to capitalize on its innovative therapies and strong partnerships.

Learn more about TBPH stock on TipRanks’ Stock Analysis page.